Health Affairs June 12, 2024
The COVID-19 pandemic accelerated the adoption of community-based (decentralized) clinical trials, telemedicine, remote monitoring of trial participants, and other novel clinical research methods that enabled crucial drug and vaccine development to continue while minimizing COVID-19 exposure to patients, providers, and researchers.
As a result, today, we have safe and effective COVID-19 vaccines and a host of new therapies, all products of the innovations—from mobile recruiting efforts to telemedicine visits to direct shipping of investigational products—that allowed clinical trials to continue. Importantly, the process also demonstrated that well-controlled trials can incorporate these innovative approaches while meeting Food and Drug Administration (FDA) standards for data integrity, minimization of research bias, and patient protection.
It’s impossible to “unsee” the benefits of community-based clinical...
Today's Sponsors
Today's Sponsor